NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT02571036 2023-12-13A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesDeciphera Pharmaceuticals, LLCPhase 1 Completed282 enrolled
NCT02859415 2022-04-05Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary MetastasesNational Institutes of Health Clinical Center (CC)Phase 1/2 Terminated3 enrolled 10 charts
NCT04697446 2021-08-10External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLCBlueprint Medicines CorporationUnknown279 enrolled
NCT00753415 2015-03-17A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)Merck Sharp & Dohme LLCPhase 1 Completed37 enrolled 10 charts